Albapure 20% solution

Marketed by Dexa Medica

Ingredients in every 100 ml

Human Albumin 20000 mg

Each package contains

1 vial of 100 ml

Other details

Dosage form:Solution for infusion
Flavour: None

W.H.O. classification

ATC Level 1: B - Blood and blood forming organs
ATC Level 2: B05 - Blood Substitutes and Perfusion Solutions
ATC Level 3: B05A - Blood and Related Products

Warnings

Pregnancy

CAUTIONThis item may not be safe for use during pregnancy. Use with caution and after consultation with your doctor.

Lactation

CAUTIONThis item may not be safe for use during lactation. Use with caution.

Alcohol

CONSULT YOUR DOCTORSafety of this item for use with alcohol has not been established. Please consult your doctor.

Machinery

CONSULT YOUR DOCTORSafety of this item for use while operating heavy machinery has not been established. Please consult your doctor.

Available in

Indonesia

Dosage information

FOR ALL AGES
The dose required depends on the size of the patient, the severity of trauma or illness and on continuing fluid and protein losses. Measures of adequacy of circulating volume and not plasma albumin levels should be used to determine the dose required. If human albumin is to be administered, haemodynamic performance should be monitored regularly; this may include:
– arterial blood pressure and pulse rate
– central venous pressure
– pulmonary artery wedge pressure
– urine output
– electrolyte
– haematocrit/haemoglobin

HYPOPROTEINAEMIA IN ACUTELY ILL PATIENTS
The usual daily dose is 50-75 g human albumin (250-375 ml of Albapure 20). The rate of administration should not exceed 2 ml per minute, as more rapid infusion may precipitate circulatory overload and pulmonary oedema. The infusion of Albapure 20 is not justified in hypoproteinaemic state associated with chronic cirrhosis, malabsorption, protein losing enteropathies, pancreatic insufficiency or undernutrition.

SHOCK
The precise nature and strength of the crystalloid solution will depend on the requirements of the patient for electrolytes and fluid. The dose should be determined by the patient's condition and response to treatment. The usual initial dose of 20 g human albumin (100 ml of Albapure 20) may be administered as a blood volume expander at a rate of 2 to 4 ml per minute. The rate of infusion may be increased in emergencies and repeated in 15 to 30 minutes if necessary. The total dose should not exceed the level of albumin found in the normal individual i.e. about 2 g per kg body weight in the absence of active bleeding.

SEVERE BURN
The usual dose is 20-80 g human albumin (100-400 ml of Albapure 20) given daily at the rate of about 1 ml per minute. Beyond 24 hours, Albapure 20 can be used to maintain plasma colloid osmotic pressure. A reasonable goal is the maintenance of a plasma albumin concentration 0f 25 g/L or a colloid osmotic pressure of 20 mmHg. The continuing need for albumin is occasioned by losses from denuded areas and decreased albumin synthesis.

MONITORING ADVICE
It is recommended that blood pressure is monitored during administration of Albapure 20. To avoid circulatory overload the rate and volume of infusion should be monitored frequently.
Myocardial function should also be monitored e.g. central venous pressure, arterial pressure and pulse rate. It is also recommended that plasma electrolytes, prothrombin time, biochemistry and haematological status should be monitored.

Indication

Hypoproteinaemia in the acutely ill patient
Albapure 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy.

Shock
Albapure 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma.

Severe burns
Extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins, resulting in hypovolaemic shock and circulatory failure.

Iso-oncotic albumin solution is the preferred replacement material. If the patient's serum albumin level is not maintained, concentrated albumin (20%) may be indicated. If exchange occurs less frequently than once a week, less concentrated colloids may be appropriate.

Disclaimer

The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for informational purposes only. This tool may not cover all possible drug interactions or all warnings or alerts. Please check with a physician if you have health questions or concerns about interactions or go to the appropriate government authority for a comprehensive list of medical warnings. Although we attempt to provide accurate and up-to-date information, no guarantee is made to that effect.

All of the content present on this website, including written text, photographs, videos, graphics, and other resources we might include (these will fall under the collective term of “website”), is meant to educate and should not be perceived as a substitution for professional medical advice, diagnosis or treatment. You should not resort to the website information to arrive at a diagnosis or treatment solution for your health problems or various medical conditions. It does not replace medical care, provided by a medical specialist. In the situation, you have specific symptoms and you might suspect that you are suffering from a medical problem, it is for the best to consult your physician.